Effects of intranasal azelastine on the response to nasal allergen challenge
| Autor: | Paraya Assanasen, Lauran Haney, Supinda Saengpanich, Robert M. Naclerio, Fuad M. Baroody, Marcy deTineo |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Nasal Provocation Tests medicine.medical_treatment Nasal congestion medicine.disease_cause Nasal provocation test Allergen Double-Blind Method medicine Humans Methacholine Chloride Eosinophil cationic protein Cross-Over Studies business.industry Rhinitis Allergic Seasonal Nasal Lavage Fluid Azelastine Treatment Outcome Otorhinolaryngology Immunology Phthalazines Methacholine Antihistamine Nasal administration Female medicine.symptom Inflammation Mediators business medicine.drug |
| Zdroj: | The Laryngoscope. 112(1) |
| ISSN: | 0023-852X |
| Popis: | Objectives/Hypothesis Azelastine, a second-generation H1-receptor antagonist, is available for topical administration. The aim of the study was to evaluate the effects of topical intranasal azelastine on the early-phase and the late-phase allergic responses and on nasal hyper-responsiveness to methacholine. Study Design Double-blind, placebo-controlled, two-way crossover study in 20 subjects with seasonal allergic rhinitis, out of their allergy season. Methods Subjects were randomly assigned to receive either placebo or two puffs of azelastine twice a day (548 μg/d) for 2 weeks followed by nasal challenge with allergen. Twenty-four hours later, while still receiving treatment, subjects underwent a nasal lavage and a nasal challenge with methacholine. End points included symptom scores, levels of mediators and number of eosinophils in nasal lavages, and the weight of secretions after methacholine challenge. Results Compared with placebo, treatment with intranasal azelastine resulted in significant reductions in allergen-induced sneezing, rhinorrhea, itching, nasal congestion, and levels of albumin during the early-phase response (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text